KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -5.584 25 days ( 28.48 % )
Last Price $12.88 1.42 %
High/ Low $12.43 - $13.06 -10.78%
Chg 7 Days -11.78 % $14.60 $12.88
Chg 30 Days -26.44 % $17.51 $12.88
Chg 12 mos -53.59 % $27.75 $12.88
Trend - 3 mos -23.76 % Width: 33.88 %
Trend - 12 mos -25.47 % Width: 194.48 %
Pred. range - 3 mos $9.62 - $12.88 -25.32 % - -0.0256 %
Pred. range - 12 mos $5.48 - $16.13 -57.48 % - 25.21 %
Short MA avg 3 mos Sell Apr 09, 2024 - 14 days
Long MA avg 3 mos Buy Mar 20, 2024 - 27 days
Short/Long MA avg 3 mos Buy Mar 06, 2024 - 37 days
Short MA avg 12 mos Buy Mar 20, 2024 - 27 days
Long MA avg 12 mos Buy Mar 20, 2024 - 27 days
Short/Long MA avg 12 mos Sell Mar 22, 2024 - 25 days
Pivot Short Buy Apr 25, 2024 - 2 days
Bollinger Buy Apr 16, 2024 - 9 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Viridian Therapeutics, Inc.

Viridian Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ... VRDN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT